AGARWALEYE Dr. Agarwal's Health Care Q2 FY27 results (Jul–Sep 2026) and concall
Management summary
- Dr. Agarwal's Health Care delivered robust performance in Q2 FY27, driven by strong same-store sales growth of 18.8% and rapid Greenfield execution.
- The company added 21 facilities in Q2 alone, prompting management to raise its full-year expansion target to 65 centers and capex guidance to ₹500 crores.
- Profitability expanded meaningfully, with Q2 PAT up 55.8% YoY to ₹57 crores despite absorbing ₹42 crores in H1 startup losses from recent expansion cohorts.
Source: Inve concall analysis and management guidance record.
Highlights
-
Revenue from operations rose 31.4% YoY to ₹655 crores for Q2 FY27, with SSSG delivering 18.8% in Q2 and 17.7% in H1
-
PAT grew 55.8% YoY to ₹57 crores in Q2 FY27, with PAT margin expanding by 134 basis points to 8.5%
-
Record quarterly network expansion with 21 facilities added (19 Greenfield, 2 acquired in Delhi NCR), taking total network to 324 facilities across 172 cities
-
High-margin lenticular refractive procedures (SMILE) surged 41.9% YoY and Femto cataract procedures grew 25.5% YoY in H1 FY27
What they filed
Q2 FY27: revenue up 32.3%, net profit up 91.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 268 | 281 | 302 | 427 | 335 +25% | 348 +24% | 526 +74% | 565 +32% |
| EBITDA | 65 | 73 | 67 | 109 | 80 +23% | 92 +26% | 139 +107% | 145 +33% |
| Net profit | 8 | 27 | 10 | 23 | 14 +75% | 11 −59% | 40 +300% | 44 +91% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Capacity
Total Facility Additions Capacity · FY27 · High confidence 65 facilities
Previously 60 facilities → 65 facilities
Surgical Facility Additions Capacity · FY27 · High confidence 55 surgical facilities
Previously 40 surgical facilities → 55 surgical facilities
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Potential Regulatory Price Caps on Medical Devices and Intraocular Lenses (IOLs) Evasive
However, given that the discussions are ongoing between the Supreme Court and the government, I think it will be premature right now for us to comment on that in terms of whether it's a risk or not. What would be the thinking, how would it all pan out, what would be the control?
Regulatory margin caps on lenses/implants pose a structural risk to hospital gross margins, but management deflected taking a stance while discussions remain in court.
Asked by Harith Ahamed
Doctor Attrition Levels and Fellowship Retention Partial
So, our attrition levels have been around 14%, 15%, but I don't want to give you inaccurate number... senior level, the attrition is less than about 1% to 2%... On this fellowship also, we will have to come back to you, Diya. I don't have the exact details offhand right now in te
Clinical talent onboarding and surgeon retention are core bottlenecks to scaling Greenfield eye hospitals sustainably.
Asked by Diya Shah
Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 6 risks, concerns & management red flags
- 4 watchlist triggers for Q3 FY27
- +6 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





